Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

Experimental Hematology & Oncology - Tập 9 Số 1 - 2020
Liqing Ning1, Chuanyu Hu2, Pingfan Lu1, Yimei Que1, Dengju Li1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
2Department of Stomatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Tóm tắt

AbstractBackgroundOutcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to evaluate the global burden of CML.MethodsAll data used in our study came from the Global Burden of Disease (GBD) study 2017. Incidence cases, death cases, disability-adjusted life-years (DALYs), and its corresponding age-standardized rate between 1990 to 2017 were used to describe the distribution of CML burden, according to age, sex, social-demographic index (SDI), and countries. Data about attributable risk factors contributing to CML deaths and DALYs were also extracted and analyzed.ResultsGlobally, the disease burden of CML gradually decreased from 1990 to 2017. Higher SDI countries achieved a remarkable effect on diminishing the CML burden. Conversely, due to population growth, the incidence cases, death cases, and DALYs of CML in lower SDI quintiles showed an upward trend. India had the most incidence cases and death cases of CML in the world. Additionally, smoking was the most significant attributable risk factor contributing to CML deaths and DALYs, followed by high body mass index.ConclusionThe disease burden of CML decreased globally, especially in higher SDI countries in the past 28 years. The increasing incidence cases and death cases were mainly observed in lower SDI countries. Additionally, strategies to control modifiable risk factors such as smoking and high body mass index might be useful in diminishing mortality and DALYs.

Từ khóa


Tài liệu tham khảo

Mughal TI, Radich JP, Deininger MW, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016;101:541–58.

Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007;370:342–50.

Mendizabal AM, Younes N, Levine PH. Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia. Int J Hematol. 2016;103:70–8.

Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. 2002;108:180–202.

Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist. 2004;9:259–70.

Shanmuganathan N, Hiwase DK, Ross DM. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leuk Lymphoma. 2017;58:2799–810.

Bower H, Björkholm M, Dickman PW, et al. Life expectancy of patients with chronic Myeloid Leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

Chihara D, Ito H, Matsuda T, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist. 2012;17:1547–50.

Delord M, Foulon S, Cayuela JM, et al. The rising prevalence of chronic myeloid leukemia in France. Leuk Res. 2018;69:94–9.

Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186-193.

Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18(Suppl 1):i3–8.

Lin L, Yan L, Liu Y, et al. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 2019;12:96.

GBD 2017 DALYs and HALE Collaborators Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1859–1922.

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1789–1858.

GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1923–1994.

Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.

Thielen N, Visser O, Ossenkoppele G, Janssen J. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. Eur J Haematol. 2016;97:145–54.

Gomez-de-León A, Gómez-Almaguer D, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Rev Hematol. 2017;10:809–19.

Kurtovic-Kozaric A, Hasic A, Radich JP, et al. The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol. 2016;172:420–7.

Pasquini MC. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. Hematology. 2012;17(Suppl 1):S79-82.

Gómez-Almaguer D, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Ruiz-Argüelles GJ. The treatment of CML at an environment with limited resources. Hematology. 2016;21:576–82.

Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346–57.

Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020;11:493–503.

Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.

Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.

Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.

Flynn KE, Atallah E. Quality of life and long-term therapy in patients with chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016;11:80–5.

Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program. 2019;2019:433–42.

Lee SJ. Chronic myelogenous leukaemia. Br J Haematol. 2000;111:993–1009.

de Haan G, Lazare SS. Aging of hematopoietic stem cells. Blood. 2018;131:479–87.

Verovskaya EV, Dellorusso PV, Passegué E. Losing sense of self and surroundings: hematopoietic stem cell aging and Leukemic transformation. Trends Mol Med. 2019;25:494–515.

Kaiser A, Schmidt M, Huber O, et al. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020;34:2206–16.

Radich JP, Deininger M, Abboud CN, et al. Chronic Myeloid Leukemia, Version 12019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:1108–35.

Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19:984–9.

Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015;94(Suppl 2):S241-247.

Micheli A, Mariotto A, Giorgi Rossi A, et al. The prognostic role of gender in survival of adult cancer patients EUROCARE Working Group. Eur J Cancer. 1998;34:2271–8.

Shaw HM, Milton GW, Farago G, McCarthy WH. Endocrine influences on survival from malignant melanoma. Cancer. 1978;42:669–77.

Waldron I. Sex differences in illness incidence, prognosis and mortality: issues and evidence. Soc Sci Med. 1983;17:1107–23.

Torre LA, Islami F, Siegel RL, et al. Global Cancer in Women: Burden and Trends. Cancer Epidemiol Biomarkers Prev. 2017;26:444–57.

Islami F, Torre LA, Drope JM, et al. Global cancer in women: cancer control priorities. Cancer Epidemiol Biomarkers Prev. 2017;26:458–70.

Lauseker M, Hasford J, Saussele S, et al. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. Cancer. 2017;123:2467–71.

Bilano V, Gilmour S, Moffiet T, et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO comprehensive information systems for tobacco control. Lancet. 2015;385:966–76.

Jha P, Peto R. Global effects of smoking, of quitting, and of taxing tobacco. N Engl J Med. 2014;370:60–8.

Chaloupka FJ, Straif K, Leon ME. Effectiveness of tax and price policies in tobacco control. Tob Control. 2011;20:235–8.

Levy DT, Meza R, Zhang Y, Holford TR. Gauging the Effect of U.S. Tobacco control policies from 1965 through 2014 using SimSmoke. Am J Prev Med. 2016;50:535–42.

Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36:868–75.

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.

Rokholm B, Baker JL, Sørensen TI. The levelling off of the obesity epidemic since the year 1999–a review of evidence and perspectives. Obes Rev. 2010;11:835–46.

Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.

Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70:3–21.

Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13:72.

Thông tin
Thông tin xuất bản

Experimental Hematology & Oncology

Tập 9 Số 1

Thông tin tác giả